Check out our latest industry white papers. Browse now!
Sales & Support: +1 800 762 3361
Member Resources

On Wednesday, September 21, drug giant Johnson & Johnson began Phase 3 clinical trials that will expand to an expected 60,000 volunteers in the U.S., South Africa and a half dozen South American countries. This is the largest trial to date of all COVID-19 vaccines in development. Key features of the promising drug include the fact it does not need to be frozen and will likely only require one shot rather than two. Paul Stoffels, chief scientific officer at Johnson & Johnson, said the company may be able to determine the vaccine's safety and efficacy by the end of the year.

Login or Register for Instant Access

Subscribe Now!

(All Fields Required)

IIR Logo Globe

Site-wide Scheduled Maintenance for April 12, 2025, between 9 A.M. - 9 P.M. CST. During this time, all services will be unavailable periodically throughout the scheduled maintenance window.

×
×

Contact Us

For More Info!